RxDoctor Payments Data

Christin Giordano McAuliffe, MD

Nephrology · Murfreesboro, TNNPI 1679894034

Payments from drug & device makers

$630in general payments, 2019–2025

Across 29 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$118
  • AstraZeneca$98
  • Fresenius USA Marketing, Inc.$83
  • Amgen$74
  • Otsuka America Pharmaceutical, Inc.$71
  • Akebia Therapeutics Inc$64
  • plus $123 from 5 others

What the payments were for

  • Food & beverage$60095%
  • Education$305%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$630 in reported general payments places this provider in the 30th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$50,981
Medicare patients
208
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LupkynisVoclosporin12$178,091
VelphoroSucroferric Oxyhydroxide22$59,542
FarxigaDapagliflozin Propanediol56$39,877
AuryxiaFerric Citrate18$27,974
Sevelamer Carbonate48$10,749
MyrbetriqMirabegron13$9,056
Lanthanum Carbonate11$8,323
Losartan Potassium110$1,413
Nifedipine ErNifedipine33$1,104
Bumetanide23$773
Carvedilol81$663
Calcium Acetate15$557
Amlodipine Besylate60$499
Spironolactone38$291
Allopurinol45$279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aurinia Pharma U.S., Inc.Lupkynis$21$178,09112 claims
Fresenius USA Marketing, Inc.Velphoro$83$59,54222 claims
AstraZenecaFarxiga$98$39,87756 claims
Akebia Therapeutics IncAuryxia$64$27,97418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →